TrialA Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)
Trial details
- Registry ID
- NCT05540860
- Phase
- Phase 2
Drug research
Sevasemten Dose 1
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)NCT05540860 | EWTX | Phase 2 | Active not recruiting | 2027-01Estimated |
| Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene TherapyNCT06100887 | EWTX | Phase 2 | Active not recruiting | 2027-03Estimated |
Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy
Trial details
- Registry ID
- NCT06100887
- Phase
- Phase 2
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |